Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Making sense of the rosiglitazone controversy

Nature Reviews Cardiology volume 7, pages 366–367 (2010)Cite this article

Subjects

Whether thiazolidinediones should be used to treat patients with type 2 diabetes mellitus is controversial, as studies on the cardiovascular effects of these drugs have produced conflicting results. A trial in which rosiglitazone and glipizide were compared supports earlier findings that rosiglitazone does not have an adverse effect on the progression of coronary atherosclerosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gerstein, H. C. et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 12 1, 1176–1187 (2010).

    Article  Google Scholar 

  2. Nissen, S. E. et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299, 1561–1573 (2008).

    Article  CAS  PubMed  Google Scholar 

  3. Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279–1289 (2005).

    Article  CAS  PubMed  Google Scholar 

  4. Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457–2471 (2007).

    Article  CAS  PubMed  Google Scholar 

  5. Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomised, open-label trial. Lancet 37 3, 2125–2135 (2009).

    Article  Google Scholar 

  6. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360, 2503–2515 (2009).

  7. NIH. Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE). Trial identifier: NCT00879970. ClinicalTrials.gov [online], (2010).

  8. Goldberg, R. B. et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28, 1547–1554 (2005).

    Article  CAS  PubMed  Google Scholar 

  9. Vijay, S. K., Mishra, M., Kumar, H. & Tripathi, K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 46, 27–33 (2009).

    Article  CAS  PubMed  Google Scholar 

  10. Mikhail, N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs 17, 845–853 (2008).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Trials Unit, Mount Sinai Cardiovascular Institute, One Gustave L. Levy Place, Box 1074, New York, 10029, NY, USA

    Michael E. Farkouh & Valentin Fuster

Authors
  1. Michael E. Farkouh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentin Fuster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael E. Farkouh.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farkouh, M., Fuster, V. Making sense of the rosiglitazone controversy. Nat Rev Cardiol 7, 366–367 (2010). https://doi.org/10.1038/nrcardio.2010.69

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2010.69

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research